

**CURRICULUM VITAE**

Serap Gur, Ph.D.

Professor of Pharmacology

**DATE AND PLACE OF BIRTH:** February 17, 1961  
Golcuk, Kocaeli-Turkey

**CURRENT ADDRESS:** Department of Pharmacology  
Faculty of Pharmacy  
Ankara University,  
Tandogan, 06100  
Ankara, Turkey

**PHONE and E-mail:** (90) 312-2033137 (Pharmacology)  
(90) 312-3806022 (Home)  
(90) 541-7951508 (cell)  
serapgur@ankara.edu.tr  
serapgur@ymail.com

**EDUCATION:** 1980-1984 University of Ankara, (BS Pharmacy)  
1985-1987 University of Ankara, (MS Pharmacology)  
1987-1993 University of Ankara, (PhD student, Pharmacology)  
1993-1998 University of Ankara, PhD

**EMPLOYMENT:** 1993-1998, Ankara University; Assistant Professor of Pharmacology.  
1998-2004, Ankara University; Associate Professor of Pharmacology.  
2004- Pres, Ankara University; Professor of Pharmacology.  
2000- 2001: Scientific visitor in Royal Free Hospital, University College of London,  
(Prof. G. Burnstock lab, Royal Free and University, College Medical School, Rowland  
Hill Street, London NW 3 2PF).

**FELLOWSHIP:** 2004 Feb-2005 Aug.-Tulane University, Dept of Urology, New Orleans, LA, USA  
2007 July-2007 Nov. Tulane University, Dept of Urology  
2009 July-2009 Oct. Tulane University, Dept of Urology  
2010 July-2011 Jan. Tulane University, Dept of Urology  
2012 July-2012 Oct. Tulane University, Dept of Urology  
2013 July-2013 Sept. Tulane University, Dept of Urology  
2015 June-2015 Sept. Tulane University, Dept of Urology  
2016 June 17-2016 July 30. Tulane University, Dept of Urology

**TEACHING EXPERIENCE:**

*Ankara University, College of Pharmacy*

Appointed as an Academic Member of Faculty of Pharmacy, Ankara University on Sept 1998.

*Graduate Student Courses Taught:*

1. Pharmacology I– Antibacterial Drugs.
2. Pharmacology II– Cardiovascular Medicine.
3. Drug-Drug Interactions.

**STUDENT ADVISING:**

Since 1998, I have been training many pharmacy, MD, PhD students, research projects and grants which were completed and are still active.

**PUBLICATONS:**

**PEER REVIEWED ARTICLES**

1. Kaya E, Sikka SC, Oral DY, Ozakca I, **Gur S**. B3-Adrenoceptor Control Of Lower Genitourinary Tract Organs And Function In Male: An Overview. *Curr Drug Targets*. 2017 Jan 20.
2. Cengiz T, Kaya E, Oral DY, Ozakca I, Bayatli N, Karabay AZ, Ensari TA, Karahan T, Yilmaz E, **Gur S**. Intracavernous Injection of Human Umbilical Cord Blood Mononuclear Cells Improves Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats. *J Sex Med*. 2017 Jan;14(1):50-58
3. Peak TC, Richman A, **Gur S**, Yafi FA, Hellstrom WJ. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. *Sex Med Rev*. 2016 Jan;4(1):74-84.
4. **Gur S**, Kadowitz PJ, Sikka SC. Current therapies for premature ejaculation. *Drug Discov Today*. 2016 Jul;21(7):1147-54.
5. **Gur S**, Peak T, Yafi FA, Kadowitz PJ, Sikka SC, Hellstrom WJ. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction? *BJU Int*. 2016 Sep;118(3):464-74.
6. Bastaskın T, Kaya E, Ozakca I, Yilmaz D, Bayatlı N, Akdemir AO, **Gur S**. Effects of silodosin, a selective alpha-1A adrenoceptor antagonist, on erectile function in a rat model of partial bladder outlet obstruction. *Neurourol Urodyn*. 2017 Mar;36(3):597-603

7. **Gur S**, Kadowitz PJ, Sikka SC, Peak TC, Hellstrom WJ. Overview of potential molecular targets for hydrogen sulfide: A new strategy for treating erectile dysfunction. *Nitric Oxide*. 2015 Sep 14;50:65-78.
8. Kaya E, Sikka SC, **Gur S**. A comprehensive review of metabolic syndrome affecting erectile dysfunction. *J Sex Med*. 2015 Apr;12(4):856-75.
9. **Gur S**, Sikka SC, Kadowitz PJ, Silberstein J, Hellstrom WJ. 2015 update of erectile dysfunction management following radical prostatectomy: from basic research to clinical management. *Curr Pharm Des*. 2015;21(11):1440-54.
10. **Gur S**, Yurdaarmagan B, Bayatli N, Sikka SC. Effect of short- and long-term sildenafil treatment on erectile dysfunction in rats with partial bladder outlet obstruction. *Neurourol Urodyn*. 2016 Jan;35(1):108-14.
11. Un O, Yilmaz D, Bayatli N, Kaya E, **Gur S**. Effect of short- and long-term sildenafil treatment on erectile dysfunction in rats with partial bladder outlet obstruction. *Aging Male*. 2014 Dec;17(4):248-55.
12. Yilmaz D, Bayatli N, Un O, Kadowitz PJ, Sikka SC, **Gur S**. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. *Urology*. 2014 Feb;83(2):508.e7-508.e12.
13. Oztekin CV, **Gur S**, Abdulkadir NA, Kartal M, Karabakan M, Akdemir AO, Gökkaya CS, Cetinkaya M. Analysis of pomegranate juice components in rat corpora cavernosal relaxation. *Int J Impot Res*. 2013 Aug 1.
14. **Gur S**, Peak TC, Kadowitz PJ, Sikka SC, Hellstrom WJ. Review Of Erectile Dysfunction In diabetic Animal Models. *Curr Diabetes Rev*. 2013 Nov 26
15. Hafez G, Gonulalan U, Kosan M, Arioglu E, Ozturk B, Cetinkaya M, **Gur S**. Acetylsalicylic acid protects erectile function in diabetic rats. *Andrologia*. 2013 Nov 8.
16. **Gur S**, Sikka SC, Abdel-Mageed AB, Abd Elmageed ZY, Rezk B, Pankey E, Kadowitz PJ, Hellstrom WJ. Imatinib Mesylate (Gleevec) Induces Human Corpus Cavernosum Relaxation by Inhibiting

Receptor Tyrosine Kinases (RTKs): Identification of New RTK Targets. *Urology*. 2013 Sep;82(3):745.

17. **Gur S**, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. *Expert Opin Drug Saf*. 2013 Jan;12(1):81-90.
18. **Gur S**, Kadowitz PJ, Gokce A, Sikka SC, Lokman U, Hellstrom WJ. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. *Curr Drug Metab*. 2013 Feb;14(2):265-9.
19. Pankey EA, Lasker GF, **Gur S**, Hellstrom WJ, Kadowitz PJ. Analysis of erectile responses to imatinib in the rat. *Urology*. 2013 Jul;82(1):253.e17-24.
20. Oztekin CV, **Gur S**, Abdulkadir NA, Lokman U, Akdemir AÖ, Cetinkaya M, Hellstrom WJ. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. *J Sex Med*. 2012 Jul;9(7):1773-81.
21. **Gur S**, Kadowitz PJ, Serefoglu EC, Hellstrom WJ. PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. *Curr Pharm Des*. 2012;18(34):5590-606.
22. **Gur S**, Kadowitz PJ, Sikka SC, Bivalacqua TJ, Hellstrom WJ. Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. *BJU Int*. 2012 Sep;110(6):856-62.
23. Ozturk Bulent, **Gur S**, Coskun M, Kosan M, Erdurak CS., Hafez G, Gonulalan U and Cetinkaya M. A new relaxant on human corpus cavernosum: *Ferulago syriaca* root extract African Journal of Pharmacy and Pharmacology Vol. 6(37). pp. 2652-2656, 8 October, 2012
24. Gonulalan U, Kosan M, Hafez G, Arıoglu E, Akdemir O, Ozturk B, **Gur S**, Cetinkaya M. The effect of diabetes mellitus on  $\alpha$ 1-adrenergic receptor subtypes in the bladder of rats. *Urology*. 2012 Oct;80(4):951.e9-16.

25. Gur S, Kadowitz PJ, Hellstrom WJ. Drugs of the future for Peyronie's disease. *Med Hypotheses*. 2012 Feb;78(2):305-11.
26. Ozgur-Akdemir A, Demirturk K, Karabakan M, Volkan-Oztekin C, Abdulkadir NA, Cetinkaya M, Gur S, Hellstrom WJ. Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue. *Urology*. 2011 Oct;78(4):968.e1-6.
27. Gur S, Limin M, Hellstrom WJ. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. *Expert Opin Pharmacother*. 2011 Apr;12(6):931-44..
28. Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. J The Effects of Chronic 5-Alpha-Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function. *J Sex Med*. 2011 Nov;8(11):3066-74.
29. Gur S, Kadowitz PJ, Hellstrom WJ. RhoA/Rho-kinase as a therapeutic target for the male urogenital tract. *J Sex Med*. 2011 Mar;8(3):675-87.
30. Gur S, Kadowitz PJ, Hellstrom WJ. A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats. *J Sex Med*. 2010 Oct;7(10):3341-50.
31. Gur S, Sikka SC, Knight GE, Burnstock G, Hellstrom WJ. Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil. *Asian J Androl*. 2010 May;12(3):415-21.
32. Gur S, Kadowitz PJ, Hellstrom WJ. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. *Curr Pharm Des*. 2010 May;16(14):1619-33.
33. Gur S, Kadowitz PJ, Gurkan L, Chandra S, Dewitt SY, Harbin A, Sikka SC, Agrawal KC, Hellstrom WJ. Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. *BJU Int*. 2010 Jul;106(1):78-83.

34. Gur S, Hellstrom WJ. Activation of P2Y1 and P2Y2 nucleotide receptors by adenosine 5'-triphosphate analogues augmented nerve-mediated relaxation of human corpus cavernosum. *Can Urol Assoc J.* 2009Aug;3(4):314-318.
35. Gur S, Kadowitz PJ, Abdel-Mageed AB, Kendirci M, Sikka SC, Burnstock G, Hellstrom WJ Management of erectile function by penile purinergic p2 receptors in the diabetic rat. *J Urol.* 2009 May;181(5):2375-82.
36. Gur S, Kadowitz PJ, Thammasitboon S, Lasky JA, Hellstrom WJ. Sep-Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats. *J Androl.* 2009 Oct;30(5):495-504
37. Gur S, Kadowitz PJ, Hellstrom WJ. A critical appraisal of erectile function in animal models of diabetes mellitus. *Int J Androl.* 2009 Apr;32(2):93-114.
38. Gur S, Sikka SC, Chandra S, Koka PS, Agrawal KC, Kadowitz PJ, Hellstrom WJ. Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. *BJU Int.* 2008 Dec;102(11):1651-7.
39. Gur S, Kadowitz PJ, Hellstrom WJ. A review of current progress in gene and stem cell therapy for erectile dysfunction. *Expert Opin Biol Ther.* 2008 Oct;8(10):1521-38.
40. Gur S, Sikka SC, Hellstrom WJ Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. *Expert Opin Investig Drugs.* 2008 Jun;17(6):855-64. Review.
41. Gur S, Kadowitz PJ, Hellstrom WJ. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. *Drugs.* 2008;68(2):209-29.

42. Gur S, Kadowitz PJ, Hellstrom WJ. Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview. *Curr Pharm Des.* 2007;13(31):3236-44.
43. Gur S, Kadowitz PJ, Trost L, Hellstrom WJ. Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum. *J Urol.* 2007 Oct;178(4 Pt 1):1543-8.
44. Nossaman BD, Gur S, Kadowitz PJ. Gene and stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial dysfunction. *Curr Gene Ther.* 2007 Apr;7(2):131-53.
45. Kendirci M, Pradhan L, Trost L, Gur S, Chandra S, Agrawal KC, Hellstrom WJ. Peripheral mechanisms of erectile dysfunction in a rat model of chronic cocaine use. *Eur Urol.* 2007 Aug;52(2):555-63.
46. Trost LW, Gur S, Hellstrom WJ. Pharmacological Management of Peyronie's Disease. *Drugs.* 2007;67(4):527-45.
47. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Celtek S, Hellstrom WJ. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. *J Sex Med.* 2006 Mar;3(2):242-50; discussion 250-2.
48. Kendirci M, Zsengellér Z, Bivalacqua TJ, Gur S, Usta MF, Chen M, Szabó C, Hellstrom WJ. Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. *J Urol.* 2005 Nov;174(5):2054-9.
49. Kendirci M, Nowfar S, Gur S, Jabren GW, Sikka SC, Hellstrom WJ. The relationship between the type of penile abnormality and penile vascular status in patients with Peyronie's disease. *J Urol.* 2005 Aug;174(2):632-5; discussion 635.

50. Kendirci M, Gur S, Sikka SC. Gene therapy for erectile dysfunction. *Front Biosci*. 2005 Sep 1;10:2758-69.
51. Özden E, Öztürk B, Koşan M, Tezel GG, Aki FT, Gur S, Ergen A, Özen H. Effect of sildenafil citrate on penile weight and physiology of cavernous smooth muscle in a post-radical prostatectomy model of erectile dysfunction in rats. *Urology*. 2011 Mar;77(3):761.e1-7.
52. Gur S, Irat AM. L-carnitine treatment partially restores urinary bladder function of streptozotocin diabetic rats. *Urol Int*. 2008;81(3):340-6.
53. Gür S, Karahan ST, Oztürk B, Badilli M. Effect of ascorbic acid treatment on endothelium-dependent and neurogenic relaxation of corpus cavernosum from middle-aged non-insulin dependent diabetic rats. *Int J Urol*. 2005 Sep;12(9):821-8.
54. Gür S, Dogan AU, Dogan M, Karahan ST, Can B, Hafez G, Ozgunes O, Kendirci M. Short-term effects of arsenic sulfur in deficits of contractile and relaxant responses on urinary bladder: pharmacological and structural changes. *Urol Int*. 2005;74(3):272-5.
55. Gür S. Effects of sodium selenate treatment on altered responses of left and right atria from streptozotocin-induced diabetic rats. *J Cardiovasc Pharmacol*. 2004 Jul;44(1):9-15.
56. Gür S, Cinel I. Sodium selenate partially corrects impaired functional responses in detrusor muscle in streptozotocin-induced diabetic rats. *Biol Trace Elem Res*. 2003;93(1-3):171-88.
57. Gür S, Oztürk B. Altered relaxant responses to adenosine and adenosine 5'-triphosphate in the corpus cavernosum from men and rats with diabetes. *Pharmacology*. 2000 Feb;60(2):105-12.
58. Gür S, Karahan ST. Effects of adenosine 5'-triphosphate, adenosine and acetylcholine in urinary bladder and colon muscles from streptozotocin diabetic rats. *Arzneimittelforschung*. 1997 Nov;47(11):1226-9.



59. **Gür S.** Effects of adenosine and isoprenaline in left atria from both neonatal and middle-aged noninsulin-dependent diabetic rat models. *Gen Pharmacol.* 1997 Oct;29(4):517-22.
60. Koşan M, Hafez G, Oztürk B, Ozgünes O, **Gür S**, Cetinkaya M. Effect of urothelium on bladder contractility in diabetic rats. *Int J Urol.* 2005 Jul;12(7):677-82.
61. Oztürk B, Cetinkaya M, **Gür S**, Ugurlu O, Oztekin V, Aki FT. The early effects of partial outflow obstruction on contractile properties of diabetic and non-diabetic rat bladder. *Urol Res.* 2002 Jul;30(3):178-84.
62. **Gür S**, Ari N, Oztürk Y. Increased responses to adenosine in isolated left atria from streptozotocin-diabetic rats: evidence for the involvement of hypothyroidism. *J Cardiovasc Pharmacol.* 1997 Feb;29(2):174-9.